The US Court of Appeals for the Fifth Circuit was wrong when it ruled the FDA’s regulations over abortion drug mifepristone should be rolled back, the agency said in a reply supporting its request that the US Supreme Court hear the case.
In a reply brief filed Tuesday, US Solicitor General Elizabeth Prelogar, on behalf of the Food and Drug Administration, asked the Supreme Court to grant its request for review.
The filing comes after the FDA asked the high court for review in September after the Fifth Circuit found the FDA’s regulations allowing mifepristone to be mailed, taken later ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.